CAMBRIDGE, Mass., March 1 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a
privately-held oncology drug development company, today announced that Richard
T. Dean, Ph.D., President and CEO of Xanthus, will present a company overview
and update on the Company's oncology pipeline at the 26th Annual SG Cowen
Health Care Conference on Monday, March 6th at 3:00 pm at The Boston Marriott
Copley Place Hotel.
About Xanthus Pharmaceuticals, Inc.
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel,
clinical-stage, small-molecule oncology candidates through a management team
whose accomplished track record encompasses all aspects of drug development,
from discovery through regulatory approval and commercialization. The Company
is applying its expertise both to advance its current pipeline and expand it
into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. --
kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus
Pharmaceuticals, Inc. -- john.mccarthy@xanthus.com or (617) 225-0522, x 125
SOURCE Xanthus Pharmaceuticals, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., for Xanthus Pharmaceuticals, Inc.,
+1-508-647-0209, kwatson@macbiocom.com; or John A. McCarthy, Jr.,
Senior Vice President & CFO of Xanthus Pharmaceuticals, Inc.,
+1-617-225-0522, ext. 125, john.mccarthy@xanthus.com
|
